GLP‑1 telehealth under scrutiny

U.S. regulators are pressing telehealth sellers of compounded GLP-1 weight-loss drugs just as companies like Noom push lower-dose online programs. (fda.gov) On March 3, 2026, the Food and Drug Administration said it sent 30 warning letters to telehealth companies over “false and misleading claims” about compounded GLP-1 products on their websites. The agency said some firms implied their products were the same as approved drugs or blurred who actually made the medicine. (fda.gov) The Food and Drug Administration had already moved earlier in 2025 to unwind shortage-era flexibility for compounded semaglutide after determining on February 21, 2025 that the injection shortage was resolved. The agency said its enforcement discretion for many compounders then ended on set timelines in 2025. (fda.gov) GLP-1 drugs are prescription medicines that mimic a gut hormone to reduce appetite and slow stomach emptying, which can help with weight loss and blood sugar control. Compounded versions are mixed by pharmacies for specific patient needs, but the Food and Drug Administration says those products are not agency-approved for safety, effectiveness, or quality. (fda.gov) That distinction became more important once branded supply improved. In a separate announcement two months before the March letters, the Food and Drug Administration said it intended to restrict GLP-1 active ingredients used in non-approved compounded drugs that were being mass-marketed as alternatives to approved products. (fda.gov) Novo Nordisk, which makes Wegovy and Ozempic, has been escalating its own campaign alongside the regulator. Its U.S. news archive shows a February 9, 2026 announcement about legal action against Hims & Hers over compounded products and a March 10, 2026 statement saying the company had received a Food and Drug Administration warning letter and welcomed further dialogue. (novonordisk-us.com) At the same time, telehealth sellers are not backing away from the category; they are changing the pitch. Noom’s current microdose GLP-1 page says the program uses a smaller dose than its standard plan, includes online clinician visits and coaching, and now starts at $79. (noom.com) When Noom introduced the program in August 2025, it said the starter price was $99, followed by $199 a month, and trade coverage at the time described the offer as $119 to start and $199 monthly with compounded semaglutide at lower doses. The price gap reflects how fast these offers are being revised as competition and oversight change. (noom.com) (pharmaceuticalcommerce.com) Noom says the lower-dose model is meant to reduce side effects and pair medication with habit coaching, while the Food and Drug Administration says telehealth marketing must clearly separate approved drugs from compounded copies. Those two messages are now colliding in the same market: online obesity treatment is still expanding, but the rules around sourcing, labeling, and claims are getting tighter. (noom.com) (fda.gov)